Kiniksa PharmaceuticalsKNSA
13F holders, Q3 2025 (September 30)2holders
0new positions
0sold out
$38.83avg. 13F price*
At the end of Q3 2025, 2 institutions reported holding Kiniksa Pharmaceuticals Ltd. (KNSA) in their 13F filings, unchanged from Q2 2025. 0 opened new positions and 0 sold out. The largest holders were Birchview Capital, LP ($1.2M) and Harbor Capital Advisors, Inc. ($804K).
- Company
- Kiniksa Pharmaceuticals Ltd.
- CUSIP
- G5269C101
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q2 2025 → Q3 2025: 50,226 shares sold, net −50,226 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Birchview Capital, LP | 0.88% | No change | 30,000 | $1.2M |
| Harbor Capital Advisors, Inc. | 0.06% | Reduce -70.8% | 20,700 | $804K |
"% of holder's portfolio" is KNSA's weight in each manager's 13F, not the share of Kiniksa Pharmaceuticals Ltd. the manager owns.